Logo

Eli Lilly Signs a Clinical Trial Collaboration with NIH to Evaluate Baricitinib Against COVID-19

Share this

Eli Lilly Signs a Clinical Trial Collaboration with NIH to Evaluate Baricitinib Against COVID-19

Shots:

  • The clinical research commences in NIH-led Adaptive COVID-19 Treatment Trial and will evaluate the efficacy and safety of baricitinib for hospitalized patients diagnosed with COVID-19- initiating this month in the US with a planned expansion to additional sites including EU and Asia
  • Additionally- Lilly will advance its LY3127804 (mAb against Ang2) to P-II study for pneumonia patients hospitalized with COVID-19 who are at higher risk of ARDS with its expected initiation later this month in the US
  • Baricitinib is an oral JAK1/JAK2 inhibitor with a brand name Olumiant and is an approved therapy in 65+ countries for moderately to severely active RA. The company does not anticipate any shortage for its therapies including baricitinib amid COVID-19

Click here ­to­ read full press release/ article 

Ref: Eli Lilly  | Image: Eli Lilly


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions